Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to $472000.0.

  • Biofrontera's Other Non-Current Assets rose 2323.76% to $472000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $472000.0, marking a year-over-year increase of 2323.76%. This contributed to the annual value of $383000.0 for FY2024, which is 2053.94% down from last year.
  • Latest data reveals that Biofrontera reported Other Non-Current Assets of $472000.0 as of Q3 2025, which was up 2323.76% from $535000.0 recorded in Q2 2025.
  • Biofrontera's Other Non-Current Assets' 5-year high stood at $1.4 million during Q3 2021, with a 5-year trough of $268000.0 in Q4 2021.
  • For the 5-year period, Biofrontera's Other Non-Current Assets averaged around $450062.5, with its median value being $383500.0 (2023).
  • In the last 5 years, Biofrontera's Other Non-Current Assets plummeted by 7137.65% in 2022 and then skyrocketed by 6512.35% in 2025.
  • Quarter analysis of 5 years shows Biofrontera's Other Non-Current Assets stood at $268000.0 in 2021, then increased by 19.4% to $320000.0 in 2022, then soared by 50.62% to $482000.0 in 2023, then decreased by 20.54% to $383000.0 in 2024, then rose by 23.24% to $472000.0 in 2025.
  • Its Other Non-Current Assets was $472000.0 in Q3 2025, compared to $535000.0 in Q2 2025 and $453000.0 in Q1 2025.